Celltrion Wins Approval for Omlyclo™ in Canada
Celltrion has exciting news for patients and medical professionals alike with the recent approval of Omlyclo™ by Health Canada. This makes it the first biosimilar referencing Xolair® in the country, bringing hope to many who suffer from various allergic conditions. With this approval, Omlyclo™ is poised to treat adults and adolescents with chronic idiopathic urticaria (CIU), commonly known as chronic spontaneous urticaria (CSU), as well as those dealing with allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
The Impact of Chronic Allergic Conditions
Living with chronic allergic conditions can significantly hinder a person's quality of life. Dr. Elena Netchiporouk, MD, emphasized the importance of effective treatments, stating that the impact of CIU affects both physical and emotional well-being. Despite the effectiveness of omalizumab, there remains a considerable need for innovative options to address the diverse range of allergic diseases. The arrival of Omlyclo™ fills this gap, providing a new avenue for effective treatment.
Clinical Trials Show Promise
The approval of Omlyclo™ was based on rigorous clinical evidence derived from a Phase III clinical trial. This trial aimed to evaluate the safety, efficacy, and overall performance of Omlyclo™ relative to the reference omalizumab in patients with CIU, showing promising results up to Week 40. The findings underscored the therapeutic equivalence between Omlyclo™ and its reference product, assuring healthcare providers and patients alike of its reliability.
Celltrion's Commitment to Innovation
Jungyong Shin, Managing Director at Celltrion Healthcare Canada, expressed enthusiasm about the approval of Omlyclo™, reinforcing the company’s dedication to making high-quality biologic medicines accessible to Canadians. This step not only reflects the company’s capability in biologics but also highlights its commitment to meet critical health needs across the nation. With a diverse pipeline in immunology and oncology, Celltrion is strategically positioned to enhance patient care in the realm of respiratory and allergy treatments.
What is Omlyclo™?
Omlyclo™ stands out as the first anti-IgE antibody biosimilar approved by Health Canada that references Xolair® (omalizumab). It is designed for both adults and adolescents aged 12 and above with chronic idiopathic urticaria, as well as adult patients suffering from chronic rhinosinusitis with nasal polyps. Patients will be able to receive Omlyclo™ through subcutaneous injections available in two strengths: 75 mg/0.5 mL and 150 mg/1.0 mL. This presents a helpful option for many seeking effective relief from their symptoms.
About Celltrion
Celltrion is a biopharmaceutical company based in Incheon, South Korea, renowned for its research and development of innovative therapeutic solutions that elevate the quality of life for individuals globally. The organization prioritizes delivering high-quality and cost-effective healthcare options through its expansive network that spans over 110 countries. With the approval of Omlyclo™, Celltrion’s portfolio now includes five biosimilars recognized by Health Canada, contributing to a better future for patients dealing with various chronic conditions.
Frequently Asked Questions
What is Omlyclo™?
Omlyclo™ is a biosimilar referencing Xolair® (omalizumab), recently approved by Health Canada for treating certain allergic conditions.
Why is the approval of Omlyclo™ significant?
The approval of Omlyclo™ represents the first omalizumab biosimilar in Canada, opening new opportunities for patients needing effective treatment options.
Who can benefit from Omlyclo™?
Omlyclo™ is indicated for adults and adolescents with chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps.
What are the forms and dosages of Omlyclo™?
Omlyclo™ will be administered as subcutaneous injections, available in 75 mg/0.5 mL and 150 mg/1.0 mL strengths.
How does Celltrion contribute to patient care?
Celltrion is dedicated to developing affordable, high-quality biologic medicines, meeting the critical needs of patients with chronic conditions.
